Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jane Street Group LLC reduced its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 75.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,727 shares of the biotechnology company’s stock after selling 252,282 shares during the quarter. Jane Street Group LLC owned about 0.12% of Aclaris Therapeutics worth $95,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. BML Capital Management LLC increased its stake in Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after purchasing an additional 1,261,866 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Aclaris Therapeutics by 1.9% during the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock valued at $3,671,000 after buying an additional 63,358 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Aclaris Therapeutics by 27.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after acquiring an additional 531,427 shares during the period. Trium Capital LLP raised its stake in Aclaris Therapeutics by 1.1% in the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock worth $2,200,000 after acquiring an additional 20,940 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Aclaris Therapeutics in the 3rd quarter worth $1,053,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Aclaris Therapeutics news, Director Anand Mehra acquired 666,666 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the completion of the acquisition, the director now owns 710,030 shares in the company, valued at approximately $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ACRS has been the subject of several research analyst reports. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Tuesday, November 19th. Cantor Fitzgerald raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, November 20th. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $3.00 to $13.00 in a report on Monday, November 18th. Finally, StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Price Performance

ACRS opened at $2.50 on Wednesday. The firm has a fifty day moving average price of $3.09 and a 200 day moving average price of $1.91. Aclaris Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $5.17. The stock has a market cap of $178.58 million, a P/E ratio of -4.81 and a beta of 0.54.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million. Equities analysts expect that Aclaris Therapeutics, Inc. will post -0.75 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.